ERBB2 and hepatocellular carcinoma: Although unlike the obvious overexpression of ErbB2 in about 30% of breast or lung cancer patients[5], there are still accumulated studies demonstrating mutations or aberrant expressions of EGFR superfamily members in HCC, such as ErbB2 overexpression or truncated ErbB2 in a certain population of HCC patients [16-18, 34].